The Food and Drug Administration has approved a new over-the-counter pill that puts acetaminophen and naproxen sodium in one tablet for 12-hour pain relief, giving consumers a new nonopioid option while keeping the same drug risks that come with each ingredient.
Quick Take
- The new product is called Tylenol with Naproxen and was approved on July 24, 2026.
- Each tablet combines 325 milligrams of acetaminophen and 110 milligrams of naproxen sodium.
- The product is cleared for adults and children 12 and older for short-term relief of minor pain.
- The approval fits a broader push for fixed-dose pain relievers that are easier to use, but not risk free.
What the FDA Approved
The Food and Drug Administration said it approved Tylenol with Naproxen, the first nonprescription fixed-dose tablet to pair acetaminophen with naproxen sodium. The agency said the product is meant for temporary relief of minor aches and pains, including headache, backache, muscle aches, toothache, menstrual cramps, and minor arthritis pain in adults and children 12 years and older.
Each tablet contains 325 milligrams of acetaminophen and 110 milligrams of naproxen sodium. The company says the pill starts working in under 30 minutes and can last up to 12 hours. That combination is designed to give people a single-dose option instead of taking two separate products at different times.
Why the Approval Matters
This approval matters because it adds another nonopioid choice at a time when many people still want simple pain relief without prescription drugs. The FDA said the approval was supported by evidence showing the combination was effective and safe, and that each ingredient helped the overall pain-relief effect. That makes the decision part medicine, part consumer convenience, and part regulatory signal.
The move also shows how drug makers keep trying to package old ingredients in new ways. Kenvue, the maker of Tylenol, says the product fills a gap between fast relief and longer relief, and the FDA says the new tablet is the first product to combine naproxen sodium with acetaminophen. The appeal is easy to see: fewer pills, one dose, and no prescription.
Safety and Limits
The new tablet is not a free pass to ignore the warnings that already apply to these drugs. The FDA and reporting on the approval both note that acetaminophen can cause liver damage if people double up with other acetaminophen products, while naproxen and other nonsteroidal anti-inflammatory drugs can raise the risk of stomach bleeding and heart problems. Those risks do not disappear because the drugs are placed in one tablet.
Kenvue wins FDA approval for first OTC acetaminophen and naproxen sodium combination https://t.co/IjwLV8yoAV FDA approval gives @kenvue a 12-hour Tylenol and naproxen product, but safety warnings and retail execution will shape its commercial impact. #Kenvue #Tylenol…
— Business-News-Today.com (@BNTBriefing) July 25, 2026
The approval also highlights a larger tension in American health care. Many people want cheaper, simpler, and safer over-the-counter pain relief, but regulators still have to weigh convenience against known drug risks. In a country where patients often manage pain on their own, a new fixed-dose tablet can look like progress, but it also shows how much responsibility still falls on the buyer.
Sources:
washingtontimes.com, fda.gov, x.com, linkedin.com
